On July 29, 2026, CMS announced the conclusion of the Part D Premium Stabilization Demonstration, effective at the end of 2026. The decision eliminates $3.6 billion in annual federal subsidies that have been flowing directly to insurance companies since 2025 to keep standalone Part D premiums from spiking. Starting January 1, 2027, those 25 million Americans on standalone Part D plans will pay premiums set entirely without that federal cushion.
This decision lands differently for the fixed-income senior at your pharmacy counter than the “less than $10” headline suggests.
What Was Actually Ended and Why It Matters
The Part D Premium Stabilization Demonstration was created by the Biden administration in 2025 to offset premium volatility that would otherwise have followed the Inflation Reduction Act’s redesign of the Medicare drug benefit. The IRA restructured Part D in ways that shifted significant costs to plan sponsors, which would normally have translated into immediate premium increases. The demonstration prevented that by paying plan sponsors directly.
The demonstration provided extra subsidies to Part D plan sponsors in two ways: reducing the base beneficiary premium, which feeds into calculations for individual plan premiums, and capping the year-over-year premium increase. In 2025, the demonstration’s first year, the base premium was reduced by $15 and the monthly premium increase was capped at $35. For 2026, these parameters were scaled back, with a base premium reduction of $10 and a maximum allowable premium increase of $50.
Without these subsidies in place for 2027, some Part D standalone plan enrollees could face larger premium increases than in recent years. The national base beneficiary premium for 2027 will be $41.33. A provision of the Inflation Reduction Act limits how fast that premium can grow, holding annual increases to no more than 6% through 2029.
In 2026, the Premium Stabilization Demonstration reduced the average standalone Part D premium by about $16 per month. Without it, the average premium would have been roughly $52 instead of the $36 most enrollees pay today.
CMS Administrator Mehmet Oz characterized the decision as returning to “traditional market conditions,” stating the subsidies were a “bailout” for insurance companies and that premiums “will go up by less than $10 for most Medicare recipients, with many even seeing lower premiums.”
The Wall Street Journal reported that nearly half of Medicare Part D plan enrollees would likely see increases largely in the $11 to $20 range per month. KFF’s rapid analysis noted that without the cap on year-over-year increases, plan-specific premium changes could be larger than CMS’s average statement implies. CMS will not publish final 2027 premiums and individual plan details until September, meaning beneficiaries do not yet know precisely how much their own coverage will cost.
The “Less Than $10” Problem on Fixed Incomes
The CMS framing is accurate in its arithmetic and incomplete in its clinical context. For the pharmacist’s patient population, the relevant frame is not what the average premium increase is. It is what $10 to $20 more per month means for a patient already managing multiple stacked cost pressures in 2026.
Medicare beneficiaries currently navigating this environment are absorbing: the GLP-1 Bridge copay structure of $50 per month that does not apply to LIS patients and does not count toward the annual out-of-pocket cap; coverage changes from the One Big Beautiful Bill that this newsletter has tracked in prior issues; 870 drug price increases from manufacturers in 2026; and the standard Part D deductible, which was $590 in 2025 and $615 in 2026.
Advocacy group Protect Our Care noted that even small premium increases could be too much for some seniors. Nearly 25 million people were enrolled in standalone Medicare Part D plans in 2026, and many are on fixed incomes where any cost increase triggers difficult choices between medications and other essential expenses.
The phrase “difficult choices between medications and other expenses” describes something pharmacists see weekly, monthly, and annually: the patient who hasn’t picked up their hypertension medication in three weeks, the patient who splits their pills because the copay is too high this month, the patient who abandons a new specialty prescription at the counter after seeing the cost-sharing amount. Premium increases don’t create this phenomenon. They add another increment to a cost burden that already produces measurable non-adherence in the Medicare population.
What Remains Protected for 2027
The premium subsidy elimination does not eliminate the structural improvements the IRA made to the Part D benefit. Several important patient protections remain intact.
The $2,000 annual out-of-pocket cap on drug spending remains in place for 2027. The $35 insulin cap remains. Medicare drug price negotiations remain active. Low-income beneficiaries receiving Extra Help (Low-Income Subsidy) are protected from premium increases. Medicare Advantage enrollees are largely insulated from this specific change, as MA-PD plans use rebates to buy down drug coverage premiums and will not be directly affected by the standalone PDP subsidy elimination.
The pharmacist counseling implication: when a patient brings up premium concerns in the context of this announcement, the response requires knowing which plan type they are on. A patient on a standalone Part D PDP will see the premium change. A patient on a Medicare Advantage plan with drug coverage will generally not. An Extra Help patient is protected from the premium increase. Getting that distinction right in the first 30 seconds of the conversation prevents both unnecessary alarm and missed counseling.
Why the AEP Window Is More Important Than Usual This Year
Annual Enrollment Period opens October 15, 2026 and runs through December 7. The plan-specific 2027 premiums will be published in mid-to-late September, approximately four to six weeks before enrollment opens.
This creates a specific clinical counseling opportunity that the pharmacist who builds it into their workflow will leverage far more effectively than the pharmacist who waits for patients to ask. When 25 million standalone Part D enrollees receive their Annual Notice of Change letters in late September showing their 2027 premiums, they will need to compare those premiums against their alternatives during a six-week decision window.
Most will not do this comparison systematically. The Medicare Plan Finder at medicare.gov allows beneficiaries to enter their specific medications and compare their out-of-pocket costs across every available plan in their zip code. Most patients do not know this tool exists. Most patients do not know that Plan A’s lower premium may cost them more in total out-of-pocket than Plan B’s higher premium if Plan B has better formulary placement for their medications.
The pharmacist who proactively contacts their Medicare patients in October, when the plan comparison letters arrive, and helps them run a specific drug list through Medicare Plan Finder, provides a service that is genuinely high-value, genuinely differentiating from what any chain or mail-order pharmacy does, and genuinely relationship-building in the way that matters most: it saves the patient real money and the patient knows the pharmacist made it happen.
The GLP-1 Bridge Interaction That Creates a Specific Counseling Priority
This newsletter covered the Medicare GLP-1 Bridge launch in detail in the July 1 issue. The premium subsidy elimination creates a specific interaction with the Bridge structure that pharmacists should understand.
The GLP-1 Bridge copay of $50 per month does not count toward the beneficiary’s annual out-of-pocket cap and does not qualify for LIS cost-sharing subsidy reductions. A patient who was enrolled in the GLP-1 Bridge for weight management and who also faces a higher 2027 Part D premium on their standalone plan is absorbing two simultaneous Medicare cost increases in 2027.
For that specific patient, the AEP plan comparison is not a routine annual exercise. It is a financial management conversation with real clinical stakes, because the premium increase and the GLP-1 Bridge copay together may push the total monthly Medicare cost burden to a level that produces adherence failure.
The pharmacist who identifies that patient, runs the plan comparison in October, and ensures the patient selects the plan with the lowest total cost of care for their specific drug list, including both their chronic medications and GLP-1 therapy, is providing financial counseling that directly prevents the silent non-adherence that costs health systems far more than any pharmacy consultation.
Building the AEP Service Before October
The pharmacies that come out of AEP with deepened patient loyalty are the ones that build their Medicare plan review service before October 15, not after the letters arrive and patients are already confused.
Build a simple template now: a list of your patient’s current medications, their current plan, and the steps to run a Medicare Plan Finder comparison. Train your staff to identify which of your Medicare patients are on standalone Part D plans versus Medicare Advantage. Build a late September outreach list: every standalone Part D patient receives a proactive contact the week their Annual Notice of Change arrives, before they call the 1-800 number on the letter.
The conversation is simple: “You’ll be receiving a letter about your 2027 Medicare drug plan in the next few weeks. I wanted to reach out before that arrives to let you know we can help you compare your options and make sure, you’re in the plan that works best for your specific medications. Can we schedule a 20-minute review?”
That call, made consistently across your Medicare patient panel in late September and early October, is the pharmacy relationship equivalent of a physician calling before a major coverage change arrives. It is rare. It is remembered. And it is the kind of service that no chain pharmacy’s loyalty program, no mail-order fulfillment center, and no DTC platform can replicate.
The subsidy ended July 29. The premium letters arrive in September. AEP opens October 15. Start building now.
Sources: Healthcare Finance News (CMS to End Medicare Subsidies for Drug Plans, July 29, 2026), Newsweek (Trump Scraps Medicare Part D Subsidy: What It Means for Seniors, July 29, 2026), Quartz / QZ (Trump Administration Ends Medicare Part D Premium Stabilization Subsidy, July 29, 2026), KFF (CMS’s Decision to End Temporary Subsidies to Medicare’s Stand-Alone Drug Plans Could Mean Larger Premium Increases for Some Beneficiaries Next Year, July 30, 2026), MedicareFAQ (Medicare Part D Subsidy Ending in 2027: What Beneficiaries Need to Know), Common Dreams (Countless Seniors Will Soon Pay More: Trump Ends Subsidy for Medicare Prescription Drug Plans, July 29, 2026), Medicare Payment Advisory Commission (MedPAC) (Part D Premium Stabilization Demonstration Financial Summary), CMS Official Announcement (Conclusion of Part D Premium Stabilization Demonstration, July 29, 2026)
